Ocular Therapeutix - OCUL Stock Forecast, Price & News

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ocular Therapeutix in the last year. There are currently 2 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" OCUL shares.
View OCUL analyst ratings or view top-rated stocks.

3 brokerages have issued 1-year price targets for Ocular Therapeutix's shares. Their OCUL share price forecasts range from $9.00 to $25.00. On average, they predict the company's share price to reach $14.50 in the next twelve months. This suggests a possible upside of 363.3% from the stock's current price.
View analysts price targets for OCUL or view top-rated stocks among Wall Street analysts.

Ocular Therapeutix's stock was trading at $6.97 at the beginning of 2022. Since then, OCUL stock has decreased by 55.1% and is now trading at $3.13.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Monday, February 27th 2023.
View our OCUL earnings forecast.

Ocular Therapeutix, Inc. (NASDAQ:OCUL) issued its quarterly earnings results on Monday, November, 8th. The biopharmaceutical company reported ($0.23) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.26) by $0.03. The biopharmaceutical company had revenue of $12.15 million for the quarter, compared to analyst estimates of $12.13 million. Ocular Therapeutix had a negative trailing twelve-month return on equity of 87.18% and a negative net margin of 119.35%. During the same period last year, the company posted ($0.17) earnings per share.

Based on aggregate information from My MarketBeat watchlists, some companies that other Ocular Therapeutix investors own include Clearside Biomedical (CLSD), Northwest Biotherapeutics (NWBO), Novavax (NVAX), Dynavax Technologies (DVAX), Omeros (OMER), Gilead Sciences (GILD), TG Therapeutics (TGTX), Inovio Pharmaceuticals (INO) and SCYNEXIS (SCYX).

Ocular Therapeutix trades on the NASDAQ under the ticker symbol "OCUL."

Ocular Therapeutix's stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (6.24%), Vanguard Group Inc. (5.13%), Deltec Asset Management LLC (3.02%), Emerald Advisers LLC (1.96%), State Street Corp (1.82%) and Emerald Mutual Fund Advisers Trust (1.41%). Insiders that own company stock include Antony C Mattessich, Opaleye Management Inc, Richard L Md Lindstrom and Summer Road Llc.
View institutional ownership trends.

Shares of OCUL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of OCUL stock can currently be purchased for approximately $3.13.

Ocular Therapeutix (NASDAQ:OCUL) has a market capitalization of $241.04 million and generates $43.52 million in revenue each year. The biopharmaceutical company earns $-6,550,000.00 in net income (profit) each year or ($1.01) on an earnings per share basis.

The company employs 228 workers across the globe.

Ocular Therapeutix's mailing address is 15 CROSBY DRIVE, BEDFORD MA, 01730. The official website for the company is www.ocutx.com. The biopharmaceutical company can be reached via phone at (781) 357-4000, via email at chris.brinzey@westwicke.com, or via fax at 781-357-4001.